Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (388)	12/3/1998 2:12:00 PM
From: Doug Meetmer	Respond to of 717

They didn't provide enough info for ANY of us to adequately interpret those releases. They should tell us, at least, where most of those patients lie-at 10% increase or 74%. In addition, we don't know if the improvements will hold up over time. We need 6 month and 12 month follow-up data. Further, they need to eventually have a randomized trial comparing photoangioplasty to conventional angioplasty with outcome measures such as mortality rate, quality of life issues. We are so early in this thing that I am not sure PCYC stock price deserves any significant boosting based upon these early results. We shall see.